sng3 Dec 2021 15:32
Timing of Synairgen Phase III nebulised Covid-19 treatment remains a challenge
By Adam Zamecnik
03 Dec 2021 (Last Updated December 3rd, 2021 15:14)
There are also concerns surrounding Synairgen SNG001’s potential inflammatory effects in advanced Covid-19.
Timing of Synairgen Phase III nebulised Covid-19 treatment remains a challenge
The Phase III trial by Synairgen is recruiting patients who require oxygen therapy via nasal prongs or mask. Credit: Shutterstock
The ideal administration timing for the Phase III Synairgen nebulised SNG001 (interferon beta-1a) asset may prove challenging to evoke the best efficacy and safety in hospitalised Covid-19, experts say. They also note concerns surrounding its potential inflammatory effects in patients with advanced disease.
While nebulisation may be a more efficient form of SNG001’s administration than previously trialled subcutaneous injection, some experts questioned the asset’s practicality in Covid-19. Some experts adds that SNG001 could perhaps perform better in milder, less-severe forms of Covid-19, considering the Phase III SPRINTER study’s (NCT04732949) focus on hospitalised subjects receiving oxygen.
Synairgen recently announced that the 610-patient SPRINTER trial has completed enrolment, with topline data expected early 2022. SNG001 is also investigated as one of the potential assets used against Covid-19 in outpatient settings in the ACTIV-2 Phase II/III study (NCT04518410) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The ACTIV-2 study has a December 2023 primary completion date. Synairgen has a market cap of USD 551.18m.
SPONSORED ARTICLE
How electrification is redefining the fleet sector?
Change is happening fast in the fleet industry and the future is electric. As electric vehicle (EV) technology improves at a staggering rate, the sector is embarking upon radically reforming its vehicle mix, the energy used and how it is purchased.
More than 100 of the world's largest businesses have now signed up to the Climate Group's EV100 campaign, making a global commitment to ensure their fleets are electric by the end of the decade. This amounts to a staggering 4.8 million vehicles and the installation of huge numbers of charging points worldwide to support them. British Gas, which runs one of the largest fleets in the UK with more than 12,000 vehicles on the road, will have a fully electric fleet by 2025.
One big challenge, however, will be the availability and visibility of charging infrastructure to support the move away from petrol and diesel. With Arval Mobility Observatory reporting that more than 60% of fleets expect to have implemented an alternative energy mix by 2023, energy retailers – traditionally the oil and gas majors operating vast networks of fuelling stations – need to adapt quickly.
Read More
SPONSORED WHITE PAPER
Solving the energy puzzle: Moving to a decarbonised future
Timing of Synairgen treatment important
By
Sign In
Follow the stocks
